Recall issued for several own label glycerine and blackcurrant cough syrups

Recall issued for several own label glycerine and blackcurrant cough syrups

June 20 2018 A Class 2 Drug Recall has been issued for 15 batches of own-brand children’s...

Bath emollients have ‘no benefit beyond standard eczema care for children’

Bath emollients have ‘no benefit beyond standard eczema care for children’

May 9 2018 A study has found no evidence of clinical benefit from including bath emollients in...

Cochrane: honey rated better for children’s cough than some OTC preps or placebo

Cochrane: honey rated better for children’s cough than some OTC preps or placebo

April 16 2018 Honey appears likely to help children’s cough more than diphenhydramine, a...

OTC Viagra Connect availability to widen following launch via Boots

OTC Viagra Connect availability to widen following launch via Boots

April 11 2018 Viagra Connect should be available from most pharmacies at the end of this week,...

MHRA issues warning over flammability of headlice treatments

MHRA issues warning over flammability of headlice treatments

March 9 2018 Pharmacists have been asked to tell customers about the risk of fire when discussing...

  • Recall issued for several own label glycerine and blackcurrant cough syrups

    Recall issued for several own label glycerine and blackcurrant cough syrups

    Wednesday, 20 June 2018 18:29
  • Bath emollients have ‘no benefit beyond standard eczema care for children’

    Bath emollients have ‘no benefit beyond standard eczema care for children’

    Wednesday, 09 May 2018 15:28
  • Cochrane: honey rated better for children’s cough than some OTC preps or placebo

    Cochrane: honey rated better for children’s cough than some OTC preps or placebo

    Monday, 16 April 2018 09:13
  • OTC Viagra Connect availability to widen following launch via Boots

    OTC Viagra Connect availability to widen following launch via Boots

    Wednesday, 11 April 2018 12:52
  • MHRA issues warning over flammability of headlice treatments

    MHRA issues warning over flammability of headlice treatments

    Friday, 09 March 2018 16:15

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

heart failureJune 20 2016

A warning advising of a risk of severe cardiac problems associated with people misusing loperamide have high dosage levels has been issued in the USA.

The US Food and Drug Administration has issued the warning in response to concerns about abuse and misuse of loperamide bought without prescription. Most reports of cardiac problems were reported in people using loperamide to self treat opioid withdrawal symptoms, or to achieve a feeling of euphoria.

The FDA has advised health professionals to be aware that loperamide used in higher than recommended doses is a possible cause of unexplained cardiac events. These include QT interval prolongation, Torsades de Pointes or other ventricular arryhthmias, syncope and cardiac arrest.

It has also pointed out that where loperamide is being abused, “individuals often use other drugs together with loperamide in attempts to increase its absorption and penetration across the blood-brain barrier, inhibit loperamide metabolism, and enhance its euphoric effects.”

An article in the Lancet has commented on the FDA advisory, saying that while a standard dose of loperamide for diarrhoea is 8mg in divided doses, “opioid users have been taking massive doses of the drug, as much as 300mg or more daily for weeks at a time. Although the number of reported cases is currently small, standard toxicology screenings do not look for loperamide, and it is possible that the rate of loperamide abuse is under-reported.”

Links:

FDA announcement

FDA Drug Safety Communication

Lancet 387: 10037; p2480. June 18 2016

OTC News

June 22 2018 A review into the scheduling of cannabis for medicinal purposes will look for “significant medical and therapeutic benefits” before a decision is made.
June 19 2018 A practice-based audit will seek to explore community pharmacy’s contribution in supporting girls and women of childbearing potential who need to take valproate medicines. Launched by...